In situ endothelialisation potential of a biofunctionalised nanocomposite biomaterial-based small diameter bypass graft

Mel, Achala de; Punshon, Geoffrey; Ramesh, Bala; Sarkar, Sandip; Darbyshire, Arnold; Hamilton, George; Seifalian, Alexander M.

doi:10.3233/bme-2009-0597

Cited by 51 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Utilization of stem cells from a human source represents a crucial step toward clinical translation of autologous TEVGs. Human adult MSCs such as bone marrow stem cells [11,12], adipose-derived stem cells [13] and endothelial progenitor cells [14] have been shown to have potential in TEVG applications. Recently, the perivascular origin of the MSCs has been shown [15–17].…”

Section: Introductionmentioning

confidence: 99%

Pericyte-based human tissue engineered vascular grafts

et al. 2010

View full text Add to dashboard Cite

The success of small-diameter tissue engineered vascular grafts (TEVGs) greatly relies on an appropriate cell source and an efficient cellular delivery and carrier system. Pericytes have recently been shown to express mesenchymal stem cell features. Their relative availability and multipotentiality make them a promising candidate for TEVG applications. The objective of this study was to incorporate pericytes into a biodegradable scaffold rapidly, densely and efficiently, and to assess the efficacy of the pericyte-seeded scaffold in vivo. Bi-layered elastomeric poly(ester-urethane)urea scaffolds (length=10mm; inner diameter=1.3mm) were bulk seeded with 3×106 pericytes using a customized rotational vacuum seeding device in less than 2 min (seeding efficiency > 90%). The seeded scaffolds were cultured in spinner flasks for 2 days and then implanted into Lewis rats as aortic interposition grafts for 8 weeks. Results showed pericytes populated the porous layer of the scaffolds evenly and maintained their original phenotype after the dynamic culture. After implantation, pericyte-seeded TEVGs showed a significant higher patency rate than the unseeded control: 100% versus 38% (p < 0.05). Patent pericyte-seeded TEVGs revealed extensive tissue remodeling with collagen and elastin present. The remodeled tissue consisted of multiple layers of α-smooth muscle actin- and calponin-positive cells, and a von Willebrand factor-positive monolayer in the lumen. These results demonstrate the feasibility of a pericyte-based TEVG and suggest that the pericytes play a role in maintaining patency of the TEVG as an arterial conduit.

show abstract

Section: Introductionmentioning

confidence: 99%

Pericyte-based human tissue engineered vascular grafts

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The beneficial properties of PCU—the reported resistance to oxidative biodegradation [24–26]—for long-term biomedical usage could thus not be exploited. Only biofunctionalization of PCUs with the bioactive RGD peptide, which is a functional domain of fibronectin, allowed relatively rapid endothelialization with endothelial progenitor cells in an animal model [27]. Therefore, additional surface modifications of PCU are necessary to improve the potential of in situ endothelialization cardiovascular prostheses.…”

Section: Discussionmentioning

confidence: 99%

In vitro Endothelialization and Platelet Adhesion on Titaniferous Upgraded Polyether and Polycarbonate Polyurethanes

Lehle

Zimmermann

et al. 2014

Materials

View full text Add to dashboard Cite

Polycarbonateurethanes (PCU) and polyetherurethanes (PEU) are used for medical devices, however their bio- and haemocompatibility is limited. In this study, the effect of titaniferous upgrading of different polyurethanes on the bio- and haemocompatibility was investigated by endothelial cell (EC) adhesion/proliferation and platelet adhesion (scanning electron microscopy), respectively. There was no EC adhesion/proliferation and only minor platelet adhesion on upgraded and pure PCU (Desmopan). PEUs (Texin 985, Tecothane 1085, Elastollan 1180A) differed in their cyto- and haemocompatibility. While EC adhesion depended on the type of PEU, any proliferative activity was inhibited. Additional titaniferous upgrading of PEU induced EC proliferation and increased metabolic activity. However, adherent ECs were significantly activated. While Texin was highly thrombotic, only small amounts of platelets adhered onto Tecothane and Elastollan. Additional titaniferous upgrading reduced thrombogenicity of Texin, preserved haemocompatibility of Elastollan, and increased platelet activation/aggregation on Tecothane. In conclusion, none of the PUs was cytocompatible; only titaniferous upgrading allowed EC proliferation and metabolism on PEUs. Haemocompatibility depended on the type of PU.

show abstract

“…3). It has been successful in cardiovascular applications such as heart valves and bypass graft because of its ideal mechanical and biochemical properties, which include biocompatibility, durability, ability for biofunctionalization and endothelialization, and antithrombogenic property [40–42]. These merits are expected to be favorable in the engineering of lymphatic graft.…”

Section: Strategies In Development Of Lymphatic Graftmentioning

confidence: 99%

“…Peptide arginine-glycine-aspartic acid (RGD), which is the minimal binding domain of fibronectin, has been studied comprehensively to increase cell adhesion on vascular grafts [42]. Peptide RGD forms receptor-ligand interactions with integrins on BEC.…”

Section: Strategies In Development Of Lymphatic Graftmentioning

confidence: 99%

Tissue-engineered lymphatic graft for the treatment of lymphedema

Kanapathy

Patel

Kalaskar

et al. 2014

Journal of Surgical Research

Self Cite

View full text Add to dashboard Cite

Background Lymphedema is a chronic debilitating condition and curative treatment is yet to be found. Tissue engineering approach, which combines cellular components, scaffold, and molecular signals hold great potential in the treatment of secondary lymphedema with the advent of lymphatic graft to reconstruct damaged collecting lymphatic vessel. This review highlights the ideal characteristics of lymphatic graft, the limitation and challenges faced, and the approaches in developing tissue-engineered lymphatic graft. Methods Literature on tissue engineering of lymphatic system and lymphatic tissue biology was reviewed. Results The prime challenge in the design and manufacturing of this graft is producing endothelialized conduit with intraluminal valves. Suitable scaffold material is needed to ensure stability and functionality of the construct. Endothelialization of the construct can be enhanced via biofunctionalization and nanotopography, which mimics extracellular matrix. Nanocomposite polymers with improved performance over existing biomaterials are likely to benefit the development of lymphatic graft. Conclusions With the in-depth understanding of tissue engineering, nanotechnology, and improved knowledge on the biology of lymphatic regeneration, the aspiration to develop successful lymphatic graft is well achievable.

show abstract

In situ endothelialisation potential of a biofunctionalised nanocomposite biomaterial-based small diameter bypass graft

Cited by 51 publications

References 24 publications

Pericyte-based human tissue engineered vascular grafts

Pericyte-based human tissue engineered vascular grafts

In vitro Endothelialization and Platelet Adhesion on Titaniferous Upgraded Polyether and Polycarbonate Polyurethanes

Tissue-engineered lymphatic graft for the treatment of lymphedema

Contact Info

Product

Resources

About